NCT00006077View on ClinicalTrials.gov

Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 31, 2000

Study Completion Date

July 31, 2003

Conditions
Parkinson's Disease
Interventions
DRUG

NS2330

DRUG

Levodopa and Domperidone

Trial Locations (1)

20892

National Institute of Neurological Disorders and Stroke (NINDS), Bethesda

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT00006077 - Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease | Biotech Hunter | Biotech Hunter